According to Merck, the company recently announced plans to launch a clinical trial of a novel multivalent human papillomavirus (HPV) vaccine aimed at providing broader protection against HPV types. At the same time, Merck plans to conduct other clinical trials to evaluate the protective efficacy and safety of the nine valent human papillomavirus vaccine (brewing yeast) (trade name: Jiada Xiu® 9) single dose vaccination regimen compared to the approved three dose vaccination regimen.